Experts discuss expanding use of vibegron for OAB

In a study presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2025 Winter Meeting in Rancho Mirage, California, investigators presented data on the β-3 agonist vibegron (Gemtesa) for the treatment of overactive bladder (OAB).¹

Urology Times^® recently interviewed 2 of the study’s authors, Grace Khaner and Melissa A. Laudano, MD. In the interview, they gave their thoughts on the potential for expanding the use of vibegron early in treatment for OAB.

“As we think about our aging population, who has increasing polypharmacy, the fewer drug-drug interactions of vibegron and the better [adverse event] profile compared with other overactive bladder medications make it a great option for treating our patients early in their treatment algorithm for overactive bladder. So now, when I see patients, I am less concerned about the [adverse events] that they may experience when starting these medications, and it really helps me to get them to treatment early on. That really improves our patient satisfaction with the care that they're getting for their overactive bladder symptoms,” said Laudano, an attending physician and an associate professor of urology at Montefiore Medical Center and Albert Einstein College of Medicine.

“There are other medications available to treat overactive bladder, but some of them do have this really difficult-to-tolerate [adverse event] profile, and with new research showing some of them are having these long-term cognitive effects. So if we're able to initiate patients early on a medication that, as far as we know, does not have those effects, like Dr Laudano was saying, we can really improve patient satisfaction and patient outcomes over time with their urinary symptoms and other health issues,” added Khaner, a medical student at Albert Einstein College of Medicine in Bronx, New York.

REFERENCE

1. Khaner G, Malviya N, Clearwater W, Laudano M. Prescribing patterns for vibegron, a selective beta3 agonist, used in the treatment of overactive bladder. Presented at: Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2025 Winter Meeting. February 26-March 1, 2025. Rancho Mirage, California. Abstract NM113